357 F. Supp. 3d 363
D.N.J.2018Background
- End-Payor Plaintiffs (EPPs) sue Wyeth and Teva alleging an anticompetitive scheme (fraudulent patents, wrongful Orange Book listings, sham litigation, and a reverse-pay settlement) that delayed generic entry of Effexor XR and caused overpayments.
- EPPs bring state-law antitrust and consumer-protection claims (class action) on behalf of purchasers across many states; Direct Purchasers pursue federal Sherman Act claims separately.
- Key factual allegations: Wyeth obtained three related method-of-use patents (’171, ’958, ’120) after serial applications; EPPs allege fraud on the PTO; Wyeth listed the patents in the Orange Book and sued multiple generics; Wyeth and Teva settled (2005) with delayed entry provisions for generic XR.
- Defendants moved for judgment on the pleadings under Rule 12(c), arguing (inter alia) federal patent preemption, statutes of limitation, state pre‑suit notice and class‑action bars, lack of state‑law standing (including Illinois Brick), and deficiencies in consumer‑protection pleadings.
- The court denied preemption and statute‑of‑limitations dismissals, applied the continuing‑violation doctrine, dismissed or permitted amendment of certain state claims based on notice/class rules and standing, and resolved other state consumer‑protection issues (some with prejudice, some without).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Federal patent preemption of state antitrust/consumer claims | EPPs: claims are antitrust/consumer-protection; preemption inapplicable | Wyeth/Teva: claims require proving patent invalidity/unenforceability, thus arise under patent law and are preempted | Denied — court follows Lipitor/Dow/Thalomid: state claims include elements distinct from patent law; not preempted at pleading stage |
| Statute of limitations (several states) | EPPs: continuing‑violation — each overcharge restarts limitations period | Defendants: claims time‑barred under short state statutes | Denied — continuing‑violation doctrine applies; purchases through July 2010 make suit filed Sept. 2011 timely |
| Pre‑filing notice and state class‑action bars (AZ, NV, UT, MA, WV, TN) | EPPs: federal Rule 23 and procedural rules displace state notice/class limits | Defendants: state statutes require notice or bar class relief | Mixed: AZ/NV/UT antitrust and MA/WV consumer claims dismissed without prejudice for failure to give statutorily required notice; TN class bar applies — Tennessee class consumer claims dismissed without prejudice (may pursue individual claims); ME notice not jurisdictional so survives |
| State‑law standing / Illinois Brick (IL, RI, UT, DC) | EPPs: may assert indirect purchaser state claims as pleaded | Defendants: Illinois and others bar indirect purchaser class actions; some states' repealers inapplicable retroactively; Utah requires resident plaintiff; DC requires a local plaintiff | Mixed: Illinois antitrust and related IL consumer claims dismissed with prejudice (IAA bars indirect purchaser classes); Rhode Island antitrust dismissed with prejudice (repealer not retroactive); Utah antitrust dismissed without prejudice (no named Utah resident); D.C. claims dismissed without prejudice for lack of Article III standing |
| Need for concerted action under certain state antitrust laws (KS, NY, TN) | EPPs: monopolization claim based on Wyeth’s conduct (and settlement) | Defendants: statutes require concerted action; unilateral conduct cannot sustain claim | Partial grant: Count I based on unilateral fraud/sham litigation by Wyeth dismissed in KS, NY, TN; monopolization claims survive to the extent based on Wyeth‑Teva reverse settlement |
| State consumer‑protection sufficiency (CA, IL, ME, NV, NM, NY, NC, RI) | EPPs: allege consumer injury from anticompetitive scheme; some statutes do not require reliance | Defendants: variously challenge reliance, consumer nexus, duplicative antitrust‑style pleading | Mixed: CA, NV, NM, NY, NC claims survive; IL and ME consumer claims dismissed with prejudice (futility); RI consumer claims dismissed with leave to amend to plead consumer status for non‑natural persons |
Key Cases Cited
- In re Lipitor Antitrust Litig., 855 F.3d 126 (3d Cir. 2017) (federal patent law does not automatically preempt state antitrust/consumer claims unless every theory requires resolution of patent law)
- In re Wellbutrin XL Antitrust Litig., 868 F.3d 132 (3d Cir. 2017) (but‑for causation analysis for antitrust injury in reverse‑payment cases)
- Shady Grove Orthopedic Assocs., P.A. v. Allstate Ins. Co., 559 U.S. 393 (2010) (Rule 23 v. state law class‑action limits; plurality/Stevens concurrence tensions)
- Dow Chem. Co. v. Exxon Corp., 139 F.3d 1470 (Fed. Cir. 1998) (state unfair‑competition claims not preempted where they include additional elements and do not conflict with patent objectives)
- Walker Process Equip., Inc. v. Food Mach. & Chem. Corp., 382 U.S. 172 (1965) (fraudulent procurement of a patent can support antitrust liability)
- Klehr v. A.O. Smith Corp., 521 U.S. 179 (1997) (continuing‑violation doctrine in antitrust pricing cases)
- Illinois Brick Co. v. Illinois, 431 U.S. 720 (1977) (bar to indirect purchasers bringing federal antitrust claims)